Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using arrhythmic risk stratification and prevention strategies

Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using... QT interval prolongation, a cardiotoxicity that increases the risk of fatal arrhythmia, is associated with several targeted cancer therapies, including tyrosine kinase inhibitors, histone deacetylase inhibitors, vascular disrupting agents, farnesyltransferase inhibitors and protein C kinase inhibitors. Because the benefits of targeted cancer therapy often outweigh the potential cardiovascular risks, tailored patient risk stratification and prevention strategies are needed in order to reduce the risk of arrhythmic complications. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs & Therapy Perspectives Springer Journals

Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using arrhythmic risk stratification and prevention strategies

Loading next page...
 
/lp/springer_journal/reduce-the-risk-of-qt-interval-prolongation-associated-with-targeted-Sviu946ncq
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Pharmacy; Pharmacy; Pharmacotherapy
ISSN
1172-0360
eISSN
1179-1977
D.O.I.
10.1007/s40267-017-0428-4
Publisher site
See Article on Publisher Site

Abstract

QT interval prolongation, a cardiotoxicity that increases the risk of fatal arrhythmia, is associated with several targeted cancer therapies, including tyrosine kinase inhibitors, histone deacetylase inhibitors, vascular disrupting agents, farnesyltransferase inhibitors and protein C kinase inhibitors. Because the benefits of targeted cancer therapy often outweigh the potential cardiovascular risks, tailored patient risk stratification and prevention strategies are needed in order to reduce the risk of arrhythmic complications.

Journal

Drugs & Therapy PerspectivesSpringer Journals

Published: Jul 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off